The biotech plans to use the cash to hustle cancer drugs licensed from Bristol-Myers and Tesaro through late-phase trials in its home nation of China.

Antengene has gained a healthy $21 million series A just a few months after setting up a deal with Celgene.

DNA-encoded library technology expert HitGen just inked a multiyear, multitarget drug discovery deal with Aduro Biotech.

Cavion has seen Spyridon "Spyros" Papapetropoulos join its ranks as EVP of research and development and CMO.

Lexicon now has data from two phase 3 trials showing the effect of the SGLT1-SGLT2 inhibitor on A1C in patients with Type 1 diabetes is sustained over 52 weeks.

The collaboration aims to drive forward research into treatments for the rare ROS1 gene mutation by gathering tissue samples from patients.

A University of Toronto team reported promising results from a trial of tiny injectable patches made from cardiac tissue.

Monday's dose of additional news of note from around the biopharma world.

German biotech CellAct has brought its cancer drug CAP7.1 through to phase 2 testing and, has now claimed the reward of a partnership with Mundipharma.